Biosimilars

Biosimilars

Increasing Provider Understanding of Biosimilars with Proactive Outreach
Ongoing education and support prepares providers to maximize the potential of biosimilars
Read the Briefing →
7 Stats That Show What Providers Think About Biosimilars
Ongoing outreach and education are key to overcoming physician hesitation, barriers to adoption
Read the Briefing →
Member Education: How We Help Build Awareness
Supporting members taking specialty medications through our many touchpoints, expertise, data
Read the briefing →
Biosimilars in the Autoimmune Category
Competition should meaningfully reduce drug costs and bring significant savings for payors
Read the briefing →
The First Biosimilar to Humira Is Here. Now What?
Robust pipeline is expected to bring significant savings in the autoimmune category
Read the briefing →
Start therapy with certainty
The Role of Biosimilars in Lowering Specialty Costs
Driving to lowest net cost means keeping all options in mind
Read the briefing →
Start therapy with certainty
Marketplace Trends Shape Specialty Landscape
Proactive monitoring and innovative strategies needed to mitigate costs
Read the briefing →
Start therapy with certainty
Keeping an Eye on the Drug Pipeline
Drugs in the pipeline to treat ophthalmic disorders include biosimilars and novel treatments
Read the briefing →
Start therapy with certainty
Expanding Therapies, Indications and Implications for Payors
Interpretation and analysis of marketplace trends including a robust drug development pipeline, transformative therapies and the growing importance of biosimilars; and implications for plan sponsors
Read the briefing →
Start therapy with certainty
Assessing New-to-Market Biologics and Biosimilars
CVS Health offers strategies for addressing new-to-market products to ensure access to clinically appropriate insulin or other medications.
Read the commentary →